{"analyses":[{"ciNumSides":"TWO_SIDED","estimateComment":"The intra-class correlation coefficient (ICC) was computed to quantify the variability in patient outcome attributable to within-center variability before any patient-level determinants are considered.","groupDescription":"ANCOVA model was used taking into account center, patient within center-level and within-patient level (over time). This appendix describes the center-level.","groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0003","paramType":"Intra-class correlation coefficient","paramValue":"0.09","statisticalMethod":"ANCOVA","testedNonInferiority":false},{"ciNumSides":"TWO_SIDED","groupDescription":"ANCOVA model was used taking into account center, patient within center-level and within-patient level (over time). This appendix describes the patient within center-level.","groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.0001","paramType":"Intra-class correlation coefficient","paramValue":"0.41","statisticalMethod":"ANCOVA","testedNonInferiority":false},{"ciNumSides":"TWO_SIDED","groupDescription":"ANCOVA model was used taking into account center, patient within center-level and within-patient level (over time). This appendix describes the within-patient level.","groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.0001","paramType":"Intra-class correlation coefficient","paramValue":"0.50","statisticalMethod":"ANCOVA","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1185"}]}]}],"denomUnitsSelected":"Participants","denoms":[{"counts":[{"groupId":"OG000","value":"1185"}],"units":"Participants"},{"counts":[{"groupId":"OG000","value":"4333"}],"units":"cycles"}],"description":"Objective 6: To examine the multilevel determinants (patient, center) of hematological outcomes of primary and secondary prophylaxis with EP2006 to better understand the variability in outcomes achieved.\n\nMean and standard error estimated from ANCOVA","groups":[{"description":"Cancer patients treated with chemotherapy and who are prescribed commercially available filgrastim biosimilar for primary or secondary prophylaxis for FN.","id":"OG000","title":"EP2006"}],"paramType":"NUMBER","populationDescription":"Evaluable sample","reportingStatus":"POSTED","timeFrame":"All cycles. Patients were evaluated at the enrollment cycle and then re-evaluated at each cycle for a maximum total of 6 cycles; however, the scheduling of these evaluations was left to the discretion of the physician, mean duration of study for 105 days","title":"Patient/Center-level Covariance Parameter Estimates of Absolute Neutrophil Count","type":"PRIMARY","typeUnitsAnalyzed":"cycles","unitOfMeasure":"participants"}